INTRODUCTION
Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatic disorder affecting older people. 1 Patients typically present with bilateral shoulder pain, morning stiffness, raised inflammatory markers, and have a rapid response to lowdose corticosteroids. There is no gold standard diagnostic test and despite being first described in 1888, controversies still exist as to its defining characteristics. PMR carries a lifetime risk of 2.4% for females and 1.7% for males. 2 The incidence in the UK has been shown to be 8.42 per 10 000 person years. 3 In the UK, the majority of patients are managed exclusively in primary care 4 6 In other individuals calcium/ vitamin D supplementation and a dualemission X-ray absorptiometry scan is recommended. 6 Although not part of this latest guidance, gastric symptoms, are commonly reported among patients with PMR. 9 Gastric protection should therefore be strongly considered especially in at-risk patients.
ONGOING MANAGEMENT
Robust clinical evidence for corticosteroid tapering is lacking. An initial dose of 15 mg of prednisolone coupled with a slow reduction in dose is effective at maintaining remission. 10 Guidance suggests 15 mg of prednisolone for 3 weeks, followed by 12.5 mg for 3 weeks, then 10 mg for 4-6 weeks, and finally a reduction in dose of 1 mg every 4-8 weeks. After initial diagnosis, follow-up to assess response within 1 week is suggested. Subsequently a review of symptoms, progress, adverse side effects, complications of treatment, atypical features, and an assessment for GCA is suggested in weeks 3 and 6 and again, 3, 6, 9, and 12 months after diagnosis. This treatment and follow-up regimen serves only as a guide and should be modified according to individual patients' response and ongoing progress. Relapses should be assessed by clinical symptoms rather than being guided by laboratory results (such as ESR and CRP). Management of relapse should involve an increase of prednisolone to the previously higher dose that controlled symptoms, followed by reassessment. 6 Recurrent relapses (more than two) are an indication for specialist referral for consideration of steroid sparing agents such as methotrexate.
PATIENT EDUCATION AND SELF-MANAGEMENT
All patients should be provided with written information on PMR and corticosteroid treatments. They should also be given information on range-of-motion exercises for the shoulder and provided with contacts to their local Polymyalgia Rheumatica & Giant Cell Arteritis UK patient support group.
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REFERRAL A wide range of illnesses can mimic PMR, some of which respond to corticosteroid therapy. Accurate diagnosis is therefore essential, ongoing management can usually continue in primary care once diagnosis has been confirmed. In cases of diagnostic uncertainty early referral for specialist review is essential. Some examples of indications for early referral are summarised in Box 2.
CONCLUSION
PMR is a commonly-seen disorder that is often managed exclusively in primary care. The BSR/BHPR guidance brings together the best evidence and extensive expert opinion to provide a much needed safe approach to the identification and ongoing management of this common inflammatory rheumatological disorder. Accurate diagnosis is key. Further early expert review should be sought in situations where diagnosis is uncertain. The guidance reinforces a more holistic approach to PMR emphasising the need to consider the prevention and management of potential side effects and complications of treatment. Dissemination of this guidance to general practice, where the majority of patients are managed, will hopefully facilitate accurate diagnosis and improve the ongoing management and, therefore, outcomes for patients with PMR.
